Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HB0017 injection dosing regimens in moderate-to-severe plaque psoriasis
CTR20222086Phase 2Completed
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HB0017 in plaque psoriasis, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Nov 2022; status: completed.
02
Drugs
HB0017
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20222086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222086.